The prognostic value of erythrocyte polyamines in the preoperative evaluation of patients with renal cell carcinoma

European Journal of Cancer

Volumn 46, Issue 10, 2010, Pages 1927-1935

  Lughezzani, Giovanni ^a,b   Karakiewicz, Pierre I ^a   Bigot, Pierre ^c,d   Perrotte, Paul ^a   Crépel, Maxime ^a,c   Rioux Leclercq, Nathalie ^c   Catros Quemener, Véronique ^c   Moulinoux, Jean Philippe ^c   Bouet, Françoise ^c   Cipolla, Bernard ^e   Patard, Jean Jacques ^c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ D'ANGERS   (France)

^e Groupe Hospitalier Privé Saint Grégoire   (France)

Author keywords

Circulating polyamines; Nephrectomy; Renal cell carcinoma; Spermidine; Spermine; Survival

Indexed keywords

SPERMIDINE; SPERMINE; TUMOR MARKER;

ACCURACY; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER MORTALITY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; ERYTHROCYTE; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PARTIAL NEPHRECTOMY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; VALIDATION STUDY; AGED; BLOOD; CARCINOMA, RENAL CELL; CHEMISTRY; EVALUATION STUDY; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PREOPERATIVE CARE;

AGED; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; ERYTHROCYTES; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PREOPERATIVE CARE; PROGNOSIS; SPERMIDINE; SPERMINE; TUMOR MARKERS, BIOLOGICAL; KAPLAN-MEIER ESTIMATE;

EID: 77953293140     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.052     Document Type: Article

References (33)

1. Karakiewicz P.I., Suardi N., Capitanio U., et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008)
2. Thomas T., and Thomas T.J. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 58 2 (2001) 244-258
3. Pegg A.E., and McCann P.P. Polyamine metabolism and function. Am J physiol 243 5 (1982) C212-C221
4. Tabor C.W., and Tabor H. Polyamines. Ann Rev Biochem 53 (1984) 749-790
5. Seiler N., Delcros J.G., and Moulinoux J.P. Polyamine transport in mammalian cells. An update. Int J Biochem Cell Biol 28 8 (1996) 843-861
6. Cipolla B., Moulinoux J.P., Quemener V., et al. Erythrocyte polyamine levels in human prostatic carcinoma. J Urol 144 5 (1990) 1164-1166
7. Cipolla B., Guille F., Moulinoux J.P., et al. Polyamines and prostatic carcinoma: clinical and therapeutic implications. Eur Urol 24 1 (1993) 124-131
8. Cipolla B.G., Ziade J., Bansard J.Y., et al. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma. Cancer 78 5 (1996) 1055-1065
9. Cipolla B., Guille F., Moulinoux J.P., et al. Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients. J Urol 151 3 (1994) 629-633
10. Bergeron C., Bansard J.Y., Le Moine P., et al. Erythrocyte spermine levels: a prognostic parameter in childhood common acute lymphoblastic leukemia. Leukemia 11 1 (1997) 31-36
11. Chatel M., Darcel F., Quemener V., Hercouet H., and Moulinoux J.P. Red blood cell polyamines as biochemical markers of supratentorial malignant gliomas. Anticancer Res 7 1 (1987) 33-38
12. Moulinoux J.P., Quemener V., Theron J., et al. Erythrocyte polyamines: their diagnostic and therapeutic importance in human neuro-oncology. Adv Exp Med Biol 250 (1988) 353-363
13. Rioux-Leclercq N., Delcros J.G., Bansard J.Y., et al. Immunohistochemical analysis of tumor polyamines discriminates high-risk patients undergoing nephrectomy for renal cell carcinoma. Hum Pathol 35 10 (2004) 1279-1284
14. Patard J.J., Leray E., Rodriguez A., et al. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol 44 2 (2003) 226-232
15. Harrell Jr. F.E., Califf R.M., Pryor D.B., Lee K.L., and Rosati R.A. Evaluating the yield of medical tests. Jama 247 18 (1982) 2543-2546
16. Volpe A., Panzarella T., Rendon R.A., et al. The natural history of incidentally detected small renal masses. Cancer 100 4 (2004) 738-745
17. Chawla S.N., Crispen P.L., Hanlon A.L., et al. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175 2 (2006) 425-431
18. Karakiewicz P.I., Trinh Q.D., Bhojani N., et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 51 6 (2007) 1616-1624
19. Bukowski R.M., Negrier S., and Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 10 18 Pt 2 (2004) 6310S-6314S
20. Yaycioglu O., Roberts W.W., Chan T., et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 58 2 (2001) 141-145
21. Cindolo L., de la Taille A., Messina G., et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 92 9 (2003) 901-905
22. Janne J., Poso H., and Raina A. Polyamines in rapid growth and cancer. Biochim Biophys Acta 473 3-4 (1978) 241-293
23. Pegg A.E. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 48 4 (1988) 759-774
24. Jacobsen J., Rasmuson T., Grankvist K., and Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163 1 (2000) 343-347
25. Negrier S., Perol D., Menetrier-Caux C., et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the Groupe Francais d'Immunotherapie. J Clin Oncol 22 12 (2004) 2371-2378
26. Li G., Feng G., Gentil-Perret A., Genin C., and Tostain J. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol 180 2 (2008) 510-513 [discussion 3-4]
27. Vasudev N.S., Brown J.E., Brown S.R., et al. Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival. Clin Cancer Res 14 6 (2008) 1775-1781
28. Kattan M.W. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95 9 (2003) 634-635
29. Karakiewicz P.I., Hutterer G.C., Trinh Q.D., et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110 6 (2007) 1241-1247
30. Coppin C., Porzsolt F., Kumpf J., Coldman A., and Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 3 (2000) CD001425
31. Karakiewicz P.I., Trinh Q.D., de la Taille A., et al. ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival. Eur J Cancer 43 6 (2007) 1023-1029
32. Karakiewicz P.I., Trinh Q.D., Lam J.S., et al. Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol 52 5 (2007) 1428-1436
33. Trinh Q.D., Karakiewicz P.I., Antebi E., et al. The presence of tumor necrosis within the primary tumor cannot independently predict renal cell carcinoma-specific mortality after nephrectomy. J Urol 177 (2007) 410